ArticleIn vivo (Athens, Greece)
Anti-gicerin Antibody Suppresses Early Pulmonary Metastatic Colonization of B16F10 Melanoma Cells.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimAdhesion of circulating melanoma cells to the pulmonary vascular bed is a critical early step in hematogenous metastasis. Gicerin is an immunoglobulin superfamily cell adhesion molecule that can mediate homophilic cell-cell adhesion. We examined whether gicerin is expressed in B16F10 melanoma cells and pulmonary tissue and whether systemic anti-gicerin antibody suppresses experimental pulmonary colonization. MATERIALS AND
methodsGicerin expression was examined by immunofluorescence staining in cultured B16F10 cells, subcutaneous B16F10 tumors, pulmonary metastatic foci, and normal lung tissue, with matched rabbit pre-immune IgG controls processed in parallel. Histopathological features of subcutaneous and pulmonary lesions were evaluated by hematoxylin and eosin staining. Nude mice received a tail-vein injection of B16F10 cells followed immediately by intravenous administration of matched rabbit pre-immune IgG or rabbit polyclonal anti-gicerin IgG. Cell proliferation, adhesion to human umbilical vein endothelial cells (HUVECs), and wound-healing migration were assessed
resultsGicerin immunoreactivity was detected in cultured B16F10 cells, subcutaneous tumors, pulmonary metastatic foci, and normal pulmonary structures, whereas matched rabbit pre-immune IgG controls showed no specific fluorescence, supporting staining specificity under the assay conditions. Tail-vein injection produced early pulmonary metastatic foci, and anti-gicerin IgG at 10 μg/mouse significantly reduced metastatic colonization compared with pre-immune IgG, whereas the 1 μg/mouse dose did not. Anti-gicerin IgG significantly inhibited B16F10 adhesion to HUVEC monolayers and significantly reduced cell migration without significantly affecting cell proliferation.
conclusionGicerin contributes to early pulmonary colonization of B16F10 melanoma cells by supporting tumor-endothelial adhesion and tumor-cell migration. Gicerin blockade may represent a potential strategy for preventing hematogenous dissemination of melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.